←back to Blog

Effect of sequential multi-dose tranexamic acid administration on perioperative blood loss in cervical posterior single-door laminoplasty and its safety

Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2026 Nov 15;40(11):1717-1723. doi: 10.7507/1002-1892.202605032.

ABSTRACT

OBJECTIVE: To investigate the effect of sequential multi-dose intravenous administration of tranexamic acid (TXA) on perioperative blood loss and inflammatory response in patients undergoing cervical posterior single-door laminoplasty (LMP), and to evaluate its safety.

METHODS: A prospective study was conducted in patients diagnosed with multi-level cervical spondylotic myelopathy, who underwent cervical posterior single-door LMP between January 2023 and June 2024. Using a computer-generated randomization table, patients were allocated into three groups. Placebo control group (group A): received 100 mL of normal saline intravenously at 30 minutes before incision (after anesthesia induction); the same dose was repeated every 5 hours for a total of 3 administrations. Single-dose control group (group B): received 1.0 g of TXA (dissolved in 100 mL normal saline) at 30 minutes before incision, followed by 100 mL of normal saline every 5 hours for a total of 2 additional doses. Sequential multi-dose group (group C): received 1.0 g of TXA (dissolved in 100 mL normal saline) at 30 minutes before incision, with an additional 1.0 g of TXA administered intravenously at 5 hours and 10 hours postoperatively, for a total dose of 3.0 g. A total of 120 patients met the selection criteria and were included in the study. After excluding lost-to-follow-up and withdrawn patients, 39 cases in group A, 37 in group B, and 38 in group C were included in the final analysis. There was no significant difference between groups (P>0.05) in age, gender, height, body weight, body mass index, comorbidities (hypertension, diabetes), and preoperative hematocrit (HCT), hemoglobin, D-dimer (D-D), interleukin 6 (IL-6), and C-reactive protein (CRP) levels. The primary outcome was total blood loss (TBL). Secondary outcomes included intraoperative blood loss (IBL), postoperative blood loss (PBL), drain removal time (DRT), HCT, D-D, IL-6, CRP, allogeneic blood transfusion rate, and incidence of complications.

RESULTS: Blood loss assessment: TBL, PBL, DRT, postoperative decline in HCT, and the allogeneic blood transfusion rate were all the lowest in group C, followed by group B, and the highest in group A, with significant differences between groups (P<0.05). The IBL was significantly lower in groups B and C than in group A (P<0.05), while there was no significant difference between groups B and C (P>0.05). Changes in inflammatory indicators: the levels of D-D and IL-6 in 3 groups reached peak at 1 day, the level of CRP reached peak at 3 days, and both decreased at 5 days, but still remained higher than preoperative levels, with significant differences (P<0.05). At different time points, the levels of D-D, IL-6, and CRP were significant lower in group C than in groups A and B (P<0.05), and in group B than in group A (P<0.05). Safety evaluation: During the 30-day postoperative follow-up, no deep vein thrombosis, pulmonary embolism, incisional infection, incisional hematoma, or TXA-related allergic reaction occurred in 3 groups.

CONCLUSION: Sequential multi-dose TXA administration effectively reduces perioperative blood loss in cervical posterior single-door LMP, suppresses postoperative hyperfibrinolysis and inflammatory response, shortens drainage duration, and does not increase the risk of thromboembolic events. This regimen represents a safe and effective optimization strategy for perioperative blood management in LMP.

PMID:43046568 | DOI:10.7507/1002-1892.202605032